Roche: IMpower132 results: difficult to compete with Merck & Co in NSCLC
Roche: (NEUTRAL, Fair Value CHF266 (+14%))IMpower132 results: difficult to compete with Merck & Co in NSCLC
Roche has published results of IMpower 132 in 1st line NSCLC. They show PFS results of the same magnitude as for Keynote-189 (Merck &Co) even if slightly lower numerically. However, we note some discrepancies in these PFS results for the low PD-L1. In addition, we were slightly disappointed regarding OS data which is far from Keynote-189 level and not statistically significant. Is it just a question of time before a positive read out at the end of the study? Difficult to say at this stage. Without positive OS data it will be impossible for Roche to compete with Merck & Co in NSCLC
Roche Holding is a healthcare company. Co. operates in two Divisions, Pharmaceuticals and Diagnostics. Co.'s pharmaceuticals division is comprised of two business segments Roche Pharmaceuticals and Chugai. Co.'s pharmaceuticals division provides therapies including Cotellic, in combination with Zelboraf for advanced melanoma, and Alecensa for a specific type of lung cancer. Co.'s diagnostics division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. Co.'s diagnostics division provides in vitro diagnostic tests, used by healthcare providers to screen, diagnose and monitor therapies.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.